Sandeep Kulkarni

R&D

Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.